Cargando…

β2-microglobulin has a different regulatory molecular mechanism between ER(+) and ER(−) breast cancer with HER2(−)

BACKGROUND: Previous studies have demonstrated that β2-microglobulin (β2M) promotes the growth and survival of a variety of cancer cells and has different regulatory effects on the expression of Bcl-2 and HER2 in HER2(−) breast cancer cells. However, β2M-mediated signaling in ER(+) and ER(−) breast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chai, Dandan, Li, Kesheng, Du, Huifen, Yang, Suisheng, Yang, Rong, Xu, Yang, Lian, Xiaowen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417228/ https://www.ncbi.nlm.nih.gov/pubmed/30866857 http://dx.doi.org/10.1186/s12885-019-5410-1

Ejemplares similares

Characterization of β2-microglobulin expression in different types of breast cancer
por: Li, Kesheng, et al.
Publicado: (2014)

Establishment and characterization of a metastasis model of human gastric cancer in nude mice
por: Li, Kesheng, et al.
Publicado: (2016)

CDX2 and Reg IV expression and correlation in gastric cancer
por: Chai, Dandan, et al.
Publicado: (2021)

Expression of ERβ, ERα and Her-2 and distribution of molecular subtypes in Uygur and Han patients with breast cancer
por: GUO, LIYING, et al.
Publicado: (2014)

Expression of Reg IV and SOX9 and their correlation in human gastric cancer
por: Zhang, Na, et al.
Publicado: (2018)

HAS2-Ezrin-ER axis plays a role in acquired antiestrogen resistance of ER-positive breast cancer
por: Sun, Xiaodan, et al.
Publicado: (2022)

Has Hawking erred?
por: Kraus, G
Publicado: (1993)

HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation
por: Park, B-W, et al.
Publicado: (2005)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma
por: Mishra, Anjali, et al.
Publicado: (2020)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Estradiol resolves pneumonia via ERβ in regulatory T cells
por: Xiong, Ye, et al.
Publicado: (2021)

ERα and ERβ Homodimers in the Same Cellular Context Regulate Distinct Transcriptomes and Functions
por: Song, Dandan, et al.
Publicado: (2022)

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2023)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

The ERβ4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERβ variants ERβ2 and ERβ5 increase aggressiveness of TNBC by regulation of hypoxic signaling
por: Faria, Michelle, et al.
Publicado: (2018)

Clinical Images: β(2)‐Microglobulin amyloidosis
por: Ștefan, Gabriel, et al.
Publicado: (2021)

ER-Phagy: A New Regulator of ER Homeostasis
por: Yang, Ming, et al.
Publicado: (2021)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
por: Collins, Denis, et al.
Publicado: (2017)

Interaction of Coumarin Phytoestrogens with ER(α) and ER(β): A Molecular Dynamics Simulation Study
por: Wang, Ting, et al.
Publicado: (2020)

Identification of ERβ1 and ERβ2 in human seminoma, in embryonal carcinoma and in their adjacent intratubular germ cell neoplasia
por: Rago, Vittoria, et al.
Publicado: (2009)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

Gene Expression-Based Predictive Markers for Paclitaxel Treatment in ER+ and ER− Breast Cancer
por: Feng, Xiaowen, et al.
Publicado: (2019)

Expression of oestrogen receptors, ERα, ERβ, and ERβ variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERα
por: Collins, Frances, et al.
Publicado: (2009)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

β2-microglobulin induces depressive- and anxiety-like behaviors in rat
por: Zhang, Ping, et al.
Publicado: (2018)

Intermolecular Alignment in β(2)-Microglobulin Amyloid Fibrils
por: Debelouchina, Galia T., et al.
Publicado: (2010)

Systemic Amyloidosis: Lessons from β(2)-Microglobulin
por: Stoppini, Monica, et al.
Publicado: (2015)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
por: Girgert, Rainer, et al.
Publicado: (2019)

Immunohistochemical expression of CD117/KIT, HER2, and Erβ in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients
por: Khalifa, Sara E.
Publicado: (2023)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

β2-adrenergic receptor regulates ER-mitochondria contacts
por: Lim, Youngshin, et al.
Publicado: (2021)

Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ERα and HER2/neu
por: Scherbakov, A. M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2po9jbctopngpblt37ululjq9c